Loading...
XSHE
002370
Market cap363mUSD
May 30, Last price  
3.51CNY
1D
0.00%
1Q
4.15%
Jan 2017
-75.74%
IPO
-46.45%
Name

Zhejiang Yatai Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
6.22
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.95%
Rev. gr., 5y
-17.97%
Revenues
421m
+12.64%
275,801,852342,668,523415,431,739429,667,249435,223,960420,339,304316,044,644313,637,218375,601,838463,145,519762,341,881906,868,6891,132,392,747709,291,124514,885,287315,134,248373,440,356420,643,619
Net income
0k
21,457,20439,087,34341,609,95148,152,15342,046,48543,794,83605,480,18140,567,97955,499,28596,800,890139,500,490150,945,987027,274,987000
CFO
15m
+21.68%
023,084,220068,261,789048,789,691031,122,81773,312,902100,934,5360127,593,60636,994,829017,806,768012,040,71914,651,745
Dividend
Jun 10, 20190.05 CNY/sh

Profile

Zhejiang Yatai Pharmaceutical Co., Ltd. researches, produces, sells, and exports pharmaceutical products in China and internationally. It offers tablets, capsules, patches, powder injections, and troches. It also provides chemical agents and raw materials, and diagnostic reagents, as well as pharmaceutical research and development outsourcing services. Zhejiang Yatai Pharmaceutical Co., Ltd. was founded in 1989 and is based in Shaoxing, China.
URL
http://www.ytyaoye.com/
IPO date
Mar 16, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
420,644
12.64%
373,440
18.50%
Cost of revenue
382,748
348,840
Unusual Expense (Income)
NOPBT
37,896
24,601
NOPBT Margin
9.01%
6.59%
Operating Taxes
313
Tax Rate
0.83%
NOPAT
37,583
24,601
Net income
Dividends
(13,883)
Dividend yield
0.53%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
50,060
51,760
Long-term debt
639,477
901,715
Deferred revenue
5,565
6,825
Other long-term liabilities
38,044
89,832
Net debt
(68,689)
142,564
Cash flow
Cash from operating activities
14,652
12,041
CAPEX
(7,459)
Cash from investing activities
(6)
Cash from financing activities
(16,840)
FCF
2,622
68,192
Balance
Cash
720,475
757,617
Long term investments
37,751
53,294
Excess cash
737,193
792,239
Stockholders' equity
609,171
809,427
Invested Capital
704,848
546,584
ROIC
6.01%
4.00%
ROCE
2.88%
1.83%
EV
Common stock shares outstanding
593,848
536,687
Price
4.29
-12.80%
4.92
9.82%
Market cap
2,547,609
-3.52%
2,640,500
9.84%
EV
2,478,920
2,783,064
EBITDA
76,601
66,215
EV/EBITDA
32.36
42.03
Interest
47,478
52,311
Interest/NOPBT
125.29%
212.64%